Süheyla OCAK, Sergülen DERVİŞOĞLU, Murat HIZ, İnci YILDIZ, Ferda ÖZKAN, Hilmi APAK, Aylin CANPOLAT, Alp ÖZKAN, Tiraje CELKAN, Serap KARAMAN

Cerrahpaşa Tıp Fakültesi çocuk osteosarkom deneyimi

Amaç: Bu çalışmada kliniğimizde tek bir merkezde tedavi görmüş Osteosarkom olguları geriye dönük olarak incelenmiştir. Gereç ve Yöntem: Kasım 1990-2004 yılları arasında COSS protokolüne göre tedavi gören 27 osteosarkornlu hastamızın sonuçlan verilmiştir. Hastalarımızın sağkalım sonuçlan Kaplan-Meier yöntemine göre hesaplanmıştır. Bulgular: Tanıda ortanca 12 yaş (5-16 yaş) olup, 25 (92,6%) olgumuz ekstremite yerleşimli iken 2 (7,4%) olgumuz aksiyal hat yerleşimli idi. 17 olgumuza ekstremite koruyucu cerrahi, 3 olgumuza ise amputasyon uygulanmıştır. Cerrahi öncesi kemoterapiye iyi histolojik yanıt (> %90 tümör nekrozu) oranımız %55'dir. Beş yıllık toplam sağkalım oranımız cerrahi öncesi kemoterapiye histolojik yanıt derecesi ile anlamlı olarak ilişkili bulunmuştur (%81,82 iyi yanıt grubuna karşılık % 55,56 kötü yanıt grubu). Çıkarımlar: Ortalama izlem süresi 75 ay (2-117 ay) olup, 5 yıllık olaysız sağkalım ve toplam sağkalım oranlan sırası ile %52,58 ve %57,52 dir.

Pediatric osteogenic sarcoma: results of Cerrahpaşa Medical Faculty

Aim: The aim of this study is to evaluate patients with osteogenic sarcoma treated at a single instate, retrospectively. Material and Method:.Between November 1990 and 2004, 27 patients with osteosarcoma were treated according to a protocol of neoadjuvant chemotherapy with Cooperative Osteosarcoma Study Group (COSS) .The survival rates were calculated by Kaplan-Meier method. Results:The median age at diagnosis was 12 years (range, 5 to 16 years). A total of 25 (92.6%) primary tumors were located in an extremity, whereas 2 (7.4%) occurred in the axial skeleton. Surgery was limb salvage in 17 patients and amputation in 3 patients .The proportion showing a good histopathological response (>90% tumour necrosis) to preoperative chemotherapy was about 55%. The 5-year overall survival was significantly related to the degree of histological response to preoperative chemotherapy (81.82% for good responders versus 55.56% for poor responders). Conclusions: The mean follow-up of all patients was 75 months (range 2-117 months). The 5-year event-free survival (EFS) and overall survival (OS) rates were 52.58 and 57.52 % respectively.

PDF

___

1. Link MP, Gebhardt MC, Meyers PA. Osteosarcoma. In: Pizzo PA, Poplack DG (eds.). Principles and Practice of Pediatric Oncology. 3rd ed. Philadelphia: J. B. Lippincott Company 1997: 1051-91.
2. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998; 9: 893-9.
3.Kager 1, Zoubek A, Pötschger U, et al. Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2003; 21: 2011-8.
4.Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study groupprotocols. J Clin Oncol 2002; 20: 776-90.
5.Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Instituto Ortopedico Rizzoli according to the Instituto Ortopedico Rizzoli/osteosarcoma 2 protocol: an up¬dated report. J Clin Oncol 2000; 18: 4016-27.
6.Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan- Kettering experience. J Clin Oncol 1992;10: 5-15.
7. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemo¬therapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6: 329 37.
8. Glasser DB, Lane JM, Huvos AG, et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma: the Memorial Hospital experience. Cancer 1992; 69: 698-708.
9. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997; 15: 76-84.
10. Meyers PA, Garlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998; 16: 2452-9.
11. Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol 1990; 8: 1988-97.
12. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteo sarcoma: a critical review. J Clin Oncol 1994;12: 423-31.
13. Pinarh FG, Dabak N, Dağdemir A. Çocukluk çağı osteosarkom olgulanmizin sonuçlan. XVI. Ulusal Kanser Kongresi 2005:156.
14. Görgün Ö, Ayan İ, Kebudi R, ve ark. Osteosarkom ve mezenkimal kondrosarkomlu olgularımızın değerlendirilmesi. Türk Hematoloji Onkoloji Dergisi 2000; 10: 199-206.